Navigation Links
Lower doses of oral contraceptives helpful in treating acne

Acne is a multifactorial disease, also known as Pimples or Zits. It is a common disorder affecting teenagers and, at times, young adults. It is caused by abnormal keratinization, increased sebum production//, bacterial infection and local inflammation of the skin, due to the blockage of skin pores. Usually acne appears on the face but can extend to neck, chest and back also.

Acne has a profound economic as well as psychosocial impact on those who suffer from its symptoms. Physicians have known for many years that oral contraceptives (OCs) can reduce the incidence of acne and help diminish acne lesions. The mechanism by which OCs improve acne most likely involves a decrease in the amount of circulating androgens. Specifically, OCs reduce total and bio-available testosterone and increase the production of sex hormone binding globulin. In addition, the steroids in OCs suppress pituitary gonadotropin secretion, thereby decreasing the levels of ovarian androgens.

An article, to be published in Contraception (available online 26 September, 2005), reviews data from clinical trials of various designs that demonstrate the efficacy of OCs in treating acne, with a focus on the trend toward treating acne with OCs containing low doses of hormones as shown in placebo-controlled trials.

The authors Johannes Huber and Katharina Walch have included clinical trials of various doses of ethinyl estradiol (EE) combined with progestins such as levonorgestrel, desogestrel, norgestimate, gestodene, cyproterone acetate and drospirenone in monophasic, triphasic and combiphasic formulations used to treat acne in women. Open-label and comparative studies beginning in the 1980s were the first to demonstrate objective and subjective reductions in the incidence of acne, severity of existing acne and seborrhea. Placebo-controlled trials have corroborated these findings with a trend toward effective acne treatment with declining doses of EE. Significant reductions in t otal, inflammatory and noninflammatory lesions compared with placebo have been demonstrated with an OC containing low dose of EE.

The authors, from the Department of Obstetrics and Gynecology, Medical University Vienna, Austria, summarize that these findings support the use of low-dose OCs for the treatment of acne, and the effectiveness of a low-dose OC in the treatment of acne should facilitate the initiation of OCs with the lowest effective hormonal dose.
'"/>




Related medicine news :

1. Simvastatin Plus Niacin May Lower Heart Risks
2. Ritalin May Lower Cocaine Abuse
3. Eating More Often May Help Lower Cholesterol
4. Lower surgical volume linked to higher death rate
5. Lowering blood pressure beneficial for PAD patients
6. Lower chance of bone fracture with Vitamin D supplementation
7. Tea Pill Lowers Cholesterol
8. Aspirin Lowers Leukemia Risk
9. Almonds Help Lower Cholesterol
10. Lowering Risk of Breast Cancer Recurrence
11. Drug to Lower Cholesterol Underused
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: